This training on Organic Labeling & Marketing will help the attendees understand the requirements of the USDA National Organic Program including the expectations in the agriculture sector. It will highlight the agricultural methods used to grow food and approved methods that integrate cultural, biological and mechanical practices.

CareTech Solutions, an information technology and Web products and services provider for U.S. hospitals, announced today that the company’s document imaging and archive solution, iDoc™ version 5.5 has achieved ONC HIT 2014 Edition Modular electronic health record (EHR) certification which designates that the software is capable of supporting eligible laboratories and hospitals with meeting the Stage 1 and Stage 2 Meaningful Use measures required to qualify for funding under the American Recovery and Reinvestment Act (ARRA).

Precipio Diagnostics, a hematology-oncology lab, has selected NovoPath™ anatomic pathology laboratory information system (APLIS) for the management and communication of data to offsite pathologists. Pioneering an innovative laboratory business model, Precipio utilizes remote pathologists at renowned academic institutions to provide high-quality, specialized readings with fast turnaround time.

Freeslate, Inc., the leading provider of high throughput research solutions for biopharmaceutical development, today announced the release of LEA 8.5. Freeslate LEA software is the leading software suite for supporting the design, execution, and analysis of high throughput experiments. LEA integrates the entire experimental process, from intuitive design of experiments through execution on Freeslate lab automation systems to the collection, analysis, and presentation of data.

As protein-based drugs become more important in treating major diseases, producers face the critical challenge of deeply characterizing these highly complex molecules for efficacy and safety, as well as to meet quality requirements. A new software tool, Thermo Scientific PepFinder, is designed to increase the speed, quality and accuracy in comprehensive biotherapeutic protein characterization during drug development and production quality control.

Partnership Helps Life Sciences Firms Increase Speed to Market While Ensuring 21 CFR Part 11 Compliance

SAN DIEGO, June 25, 2014 /PRNewswire/ -- Bloomberg BNA and law firm Robins, Kaplan, Miller, & Ciresi L.L.P, in conjunction with the Biotechnology Industry Organization, today published a study on the impact of recent U.S. Supreme Court decisions affecting the life sciences industry. The report, Stopped at the Threshold: The Practical Implications of the Supreme Court's Mayo and Myriad Decisions on Biotechnology Patent Practices, explores the impact of Supreme Court decisions handed down in 2012 and 2013 that have made it more difficult for companies in the multibillion dollar global life sciences industry to obtain patents. The report surveys the impact of the Supreme Court decisions Mayo Collaborative Services v. Prometheus Laboratories ("Mayo") and Association for Molecular Pathology v. Myriad Genetics ("Myriad") – and the U.S. Patent and Trademark Office's (PTO) interpretation of those decisions – on companies that own or license patents across the life sciences industry. The authors interviewed 24 industry legal professionals representing the biotechnology industries, including corporate representatives affected by the changes and patent attorneys who deal regularly with the PTO, and gathered commentary from PTO officials. The study also analyzed approximately 350 patent applications recently rejected by the PTO that have been impacted by these decisions. The report notes that recent interpretations of the law have "shaken the life sciences industry at its roots." Interviews with industry experts find that some of the affected companies believe the current environment "could force inventors and investors to abandon what could be life-saving projects or move to other countries where the laws facilitate innovation." The industry experts noted that the recent Supreme Court decisions, and the PTO's guidance on them, "have rewritten the playbook for biotechnology companies . . . [and] not only limit the scope of what discoveries remain patent eligible, they also transform the way the PTO's patent examiners will review life sciences applications." "The decisions made by the Supreme Court and the resulting PTO guidance have far-reaching implications for the life sciences industry," said Randy Kubetin, managing editor of Bloomberg BNA's Life Sciences Law & Industry Report. "The industry is still reverberating from the impact of these events and this report offers one-of-a-kind insight and analysis that makes it of great benefit to the entire life sciences industry." "This study demonstrates that several recent Supreme Court decisions are increasingly impacting areas of biotechnology," said Hans Sauer, Deputy General Counsel for Intellectual Property, BIO. "The United States Patent and Trademark Office's interpretation of case law has led to the rejection of patent applications on industrial or medicinal biotech products." "We were surprised to see how many claims the Patent and Trademark Office rejected on the basis of the Supreme Court's recent decisions," said Matthew McFarlane, co-author and Principal with the law firm Robins, Kaplan, Miller & Ciresi L.L.P. "It's important for inventors large and small to appreciate the wide variety of life sciences patent applications affected by relatively recent reinterpretations of the law." Tara Sharp, an associate with Robins Kaplan and co-author of the report, noted that, "The range of inventions impacted by the Supreme Court decisions and PTO guidelines is vast, and covers diverse technologies such as methods for diagnosing disease, biological products, including antibodies and proteins, and even plants and metallic compounds." An executive summary of the report is available at www.bna.com/BIO_2014_PR. About Bloomberg BNA Bloomberg BNA, a wholly owned subsidiary of Bloomberg, is a leading source of legal, regulatory, and business information for professionals. Its network of more than 2,500 reporters, correspondents, and leading practitioners delivers expert analysis, news, practice tools, and guidance — the information that matters most to professionals. Bloomberg BNA's authoritative coverage spans a full range of legal practice areas, including tax & accounting, labor & employment, intellectual property, banking & securities, employee benefits, health care, privacy & data security, human resources, and environment, health & safety. About BIO BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling "innovations transforming our world" and the BIO Newsletter is the organization's bi-weekly email newsletter. Subscribe to the BIO Newsletter. About Robins, Kaplan, Miller & Ciresi L.L.P. Robins, Kaplan, Miller & Ciresi L.L.P. (http://www.rkmc.com) is a litigation firm whose clients include numerous Fortune 500 corporations, emerging markets companies, entrepreneurs, and individuals as both plaintiffs and defendants. With more than 220 lawyers located in Atlanta, Boston, Los Angeles, Minneapolis, New York and Naples (FL), the firm is frequently engaged in high-stakes, complex litigation with significant bottom-line implications for clients. Its business lawyers handle complex transactions in a variety of market segments and industries. Chambers USA 2014 ranked the firm in the first band nationally in the Antitrust: Plaintiffcategory, and regularly gives it top rankings for litigation. Corporate Counsel has named the firm a "Go-To Law Firm" and Multicultural Law has ranked the firm as one of the top national law firms for diversity. The American Lawyer ranked the firm seventh in the country in the 2013 Pro Bono Survey, and twice named the firm to the A-List.

Ability to upload forensic samples to National DNA Index System using the highly discriminating GlobalFiler DNA chemistry enables faster, more powerful data comparisons to solve crimes in the U.S. and globally.

Agilent Technologies, Inc. and Bruker Corp. today announced an agreement to provide customers with more freedom of choice when selecting a chromatography data system for their laboratories.

Use METTLER TOLEDO's LabX Titration software to optimize your multi-instrument workflow. Benefit from a guided weighing process, simplified operation, easy sample series modifications, results storage and tailored reports.

CSols, Inc. Webinar: CSols, Inc. Webinar: “Paperless Lab” is a popular phrase being tossed around - and generating interest to achieve it - but there are many questions you must ask before diving it, like: Can you truly eliminate all paper in the lab? And should you? This webinar will answer these questions and more.

The Object Management Group® (OMG®) is pleased to announce that it will be holding the Model Based Systems Engineering (MBSE) in Healthcare Summit at the Omni Parker House in Boston, MA. The summit will take place on Wednesday, June 18thand is being sponsored by IBM.

RURO, Inc., with its solutions in use in more than 1000 laboratories around the world, today announces its recent certification from ICCBBA for ISBT 128. From ICCBBA website (http://www.ICCBBA.com): “ICCBBA enhances safety for patients by managing and promoting the ISBT 128 international information standard for use in transfusion and transplantation.”

Laboratories analyzing environmental, clinical research/toxicological and food samples have a powerful new data tool expected to save time and money while identifying compounds with high levels of confidence.

Agilent Technologies, Inc. and PREMIER Biosoft today announced that a selection of Agilent's high-resolution mass spectrometry and liquid chromatography instruments now supports PREMIER Biosoft's SimGlycan software. The combined analytical strength of Agilent instrumentation and PREMIER Biosoft's glycan and glycopeptide data analysis software will open up a new level of discovery for researchers studying the biology of disease.

EDKM is the only meeting in the US that provides answers and real user case studyexperiences in laboratory informatics systems. Although the pharma industry have been implementing these systems for over 15 years, other industries such as food and beverage, fast consumer goods and cosmetic industries have also started to implement these systems into their laboratories with the hope of not only becoming a ‘paperless lab’ but to manage their data in the most effectiveand efficient way possible.

Agilent Technologies Inc. and Cerno Bioscience today announced that Agilent will distribute Cerno Bioscience's MassWorks calibration and analysis software with all Agilent GC/MSD systems. This novel calibration technology increases the mass accuracy of Agilent's single-quadrupole GC/MSD to enable unknown compound identification. This process normally requires more complex instruments, such as time-of-flight (TOF) mass spectrometers.

Privacy Analytics Inc. (www.privacyanalytics.ca), a leading provider of data anonymization solutions for the healthcare industry, today announced the availability of a new solution to enable pharmaceutical companies to share clinical trials data while protecting the privacy of individual participants. The new offering accelerates the ability of pharmaceutical companies to meet increasing requests for individual-level participant data and clinical study reports by academic institutions, patients and other third-parties.

Leaders in industry and research will examine the challenges and solutions in collaboration to streamline drug development at the DIA 2014 50th Annual Meeting at the San Diego Convention Center from June 15 to 19.

Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today the acquisition of Amirsys. Amirsys' point-of-care decision support technology to augment Elsevier's evidence-based clinical solutions suite